LYMPHOMAS

Marginal zone lymphomas are a heterogenous group of B-cell non-Hodgkin lymphomas based on their etiology and clinical presentation, and as such, treatment for these diseases vary by subtype, according to Stephen Douglas Smith, MD.

When choosing therapy for patients with early stage Hodgkin lymphoma, considering risk scoring systems and Deauville criteria for PET-adapted therapy are key conditions for optimizing survival rates, according to Ranjana H. Advani, MD.

The most recent updated World Health Organization classification of lymphoid neoplasms included a new category of mature B-cell neoplasms, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations.

During a Targeted Oncology Case Based Peer Perspective event, Barbara Pro, MD, discussed the case of a 60-year-old male patient with peripheral T-cell lymphoma.

Lori A. Leslie, MD, discusses the approval of tazemetostat in the follicular lymphoma setting and the data that that led to its FDA approval.

“We should look to reduce or limit radiation therapy or eliminate it if it’s not necessary. The major problem is the late toxicity associated with it."

Nilanjan Ghosh, MD, PhD, discussed the case of a 22-year-old patients with advanced Hodgkin lymphoma.

The FDA accepted a supplemental New Drug Application for crizotinib and granted it a Priority Review as treatment of pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma that is positive for an ALK alteration.

In an interview with Targeted Oncology, Thomas M. Habermann, MD, reflects on the advancements he has observed in the treatment paradigm for lymphomas.

Patients with classic Hodgkin lymphoma and human immunodeficiency virus were found to have similar clinical outcomes compared with patients with cHL and no HIV, according to an analysis presented during the eighth annual virtual meeting of the Society of Hematologic Oncology.

In an interview with Targeted Oncology, Alan P. Z. Skarbnik, MD, discussed the current therapeutic strategies for treating patients with FL.

John M. Burke, MD, discusses treatment with rituximab versus obinutuzumab in patients with advanced stage follicular lymphoma with high tumor burden.

The FDA has accepted a supplemental Biologics License Application for axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma after 2 or more prior lines of systemic therapy.

The question of whether patients with asymptomatic advanced-stage follicular lymphoma should undergo watch-and-wait observation or start treatment immediately was addressed at the 2020 Debates and Didactics in Hematology and Oncology during a debate between Jean Louise Koff, MD, MS, and James O. Armitage, MD.

The FDA granted an Orphan Drug designation to tolinapant for the treatment of patients with T-cell lymphomas.

A phase 2a study is recruiting patients with relapsed or refractory B-cell non-Hodgkin lymphoma to receive the combination of MT-3724, a novel CD-20–targeting engineered toxin body and lenalidomide, according to a poster presented at the American Association for Cancer Research Advances in Malignant Lymphoma Meeting.

The FDA has accepted a New Drug Application for umbralisib as treatment of patients with previously treated marginal zone lymphoma who have received at least 1 prior regimen with anti-CD20 therapy and for patients with follicular lymphoma who have received at least 2 prior systemic therapies.

Nilanjan Ghosh, MD, discusses the significance of the data from a pilot study of lisocabtagene maraleucel in patients ineligible for second-line transplant with relapsed/refractory aggressive large B-cell non-Hodgkin lymphoma.

Early rituximab intensification during treatment with R-CHOP demonstrated no difference in outcomes as treatment of patients with diffuse large B-cell lymphoma.

Lenalidomide in combination with rituximab (Rituxan, R2) induction has the ability to achieve high rates of complete molecular response (CMR), similar to rituximab plus chemotherapy, when used as frontline therapy in patients with follicular lymphoma (FL), according to results from the phase 3 RELEVANCE trial (NCT01650701).

Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.

The FDA has approved tafasitamab-cxix in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specific, including DLBCL arising from low-grade lymphoma, and patients who are not eligible for autologous stem cell transplant.

Axicabtagene ciloleucel demonstrated a similar overall response rate in both the trial and non-trial settings as treatment of patients with relapsed or refractory large B-cell lymphoma.

The FDA has granted an Orphan Drug designation to cobomarsen for the treatment of patients with T-cell lymphoma, according to an announcement from miRagen Therapeutics.